108 related articles for article (PubMed ID: 11556390)
1. In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Kimura T
Osaka City Med J; 2001 Jun; 47(1):33-41. PubMed ID: 11556390
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Ando M; Eguchi K; Shinkai T; Tamura T; Ohe Y; Yamamoto N; Kurata T; Kasai T; Ohmatsu H; Kubota K; Sekine I; Hojo N; Matsumoto T; Kodama T; Kakinuma R; Nishiwaki Y; Saijo N
Br J Cancer; 1997; 76(11):1494-9. PubMed ID: 9400948
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
5. [Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].
Liang YJ; Fu LW; Ding Y; Xiong HY; Chen LM; Yang XP; Pan QC
Ai Zheng; 2003 Apr; 22(4):368-71. PubMed ID: 12703990
[TBL] [Abstract][Full Text] [Related]
6. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
8. The significance of the sequence of administration of topotecan and etoposide.
Bonner JA; Kozelsky TF
Cancer Chemother Pharmacol; 1996; 39(1-2):109-12. PubMed ID: 8995507
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
Bertrand R; O'Connor PM; Kerrigan D; Pommier Y
Eur J Cancer; 1992; 28A(4-5):743-8. PubMed ID: 1326304
[TBL] [Abstract][Full Text] [Related]
10. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.
Gauvin A; Bressolle F; Martineau P; Astre C; Pinguet F
Anticancer Res; 2002; 22(2A):905-12. PubMed ID: 12014670
[TBL] [Abstract][Full Text] [Related]
11. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
15. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
Oguro M; Seki Y
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
17. [Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Couteau C; Armand JP
Bull Cancer; 1998 Dec; Spec No():47-50. PubMed ID: 9932085
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Saijo N; Horiike A
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
20. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
